Digestive Diseases and Sciences

, Volume 40, Issue 6, pp 1226–1230 | Cite as

Exacerbation of primary biliary cirrhosis during interferon-α2b therapy for chronic active hepatitis C

  • T. Maeda
  • S. Onishi
  • T. Miura
  • S. Iwamura
  • A. Tomita
  • T. Saibara
  • Y. Yamamoto
Case Report

Summary

A 60-year-old woman with chronic active hepatitis C was treated with 6 million units of rIFN-α2b daily for two weeks and subsequently three times weekly for several months. Histological examination proved a severe form of chronic active hepatitis C unexpectedly complicated with primary biliary cirrhosis (PBC). Before treatment, levels of serum alkaline phosphatase (ALP) or gammaglutamyltranspeptidase (GGT) had remained within normal limits over six months, although anti-mitochondrial antibody (AMA) was shown to be positive. After eight weeks of therapy, the daily dose of rIFN was reduced to 3 million units because of a marked increase of ALP and GGT, although the serum alanine aminotransferase (ALT) was normalized. Four months later, IFN treatment was suspended because of continuous elevation of ursodeoxycholic acid was substituted. Two months later, the ALP and GGT levels returned to the normal range, although ALT was not normalized and HCV-RNA remained positive.

This is the first report case that demonstrates IFN treatment potentially exacerbates PBC associated with chronic active hepatitis C. It is important for treating physicians to keep this association in mind.

Key words

primary biliary cirrhosis hepatitis C interferon-α2b 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Di-Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant alpha interferon therapy for chronic hepatitis C. A randomized, double blind, placebo-controlled trial. N Engl J Med 321:1506–1510, 1989PubMedGoogle Scholar
  2. 2.
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Givas A, Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis with recombinant interferon alpha: A multicenter randomized, controlled trial. N Engl J Med 321:1501–1506, 1989PubMedGoogle Scholar
  3. 3.
    Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou J-P: Recombinant human alpha interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized, controlled trial from France. Hepatology 13:393–397, 1991PubMedGoogle Scholar
  4. 4.
    Schultz M, Muller R, Von zur Muhlen A, Brabant G: Induction of hyperthyroidism by interferon-alpha-2b. Lancet 1:1452, 1989 (letter)Google Scholar
  5. 5.
    Mercell P, Pouteau M, Renard P, Grynblat J-M, Colas Linhart N, Bardet P, Bok B, Benhamou J-P: Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. Gut 33:855–856, 1992PubMedGoogle Scholar
  6. 6.
    Ronnblom LE, Alm GV, Oberg KE: Autoimmunity after alpha-interferon therapy for malignant carcinoid tumor. Ann Intern Med 115:178–183, 1991PubMedGoogle Scholar
  7. 7.
    Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER: Interferon-induced chronic hepatitis. Gastroenterology 101:840–842, 1991PubMedGoogle Scholar
  8. 8.
    Shindo M, Di Bisceglie AM, Hoofnagle JH: Acute exacerbation of liver disease during interferon alpha therapy for chronic hepatitis C. Gastroenterology 102:1406–1408, 1992PubMedGoogle Scholar
  9. 9.
    Ronnblom LE, Oberg KE, Alm GV: Possible induction of systemic lupus erythematosus by interferon treatment in a patient with a malignant carcinoid tumor. Int J Med 227:207–210, 1990Google Scholar
  10. 10.
    Abdi EA, Brien W, Venner PM: Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol 36:515–519, 1986PubMedGoogle Scholar
  11. 11.
    Pangalis GA, Griva E: Recombinant alpha-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. Cancer 61:869–872, 1988PubMedGoogle Scholar
  12. 12.
    Maeda T, Loveland BE, Rowley MJ, Mackay IR: Autoantibody against dihydrolipoamide dehydrogenase, the E3 subunit of the 2-oxoacid dehydrogenase complexes: Significance for primary biliary cirrhosis. Hepatology 14:994–999, 1991PubMedGoogle Scholar
  13. 13.
    Dawson GJ, Lesniewski RR, Stewart JL, Boardway KM, Gutierrez RA, Pendy L, Johnson RG, Alcalde X, Rote KV, Devare SG: Detection of antibodies to hepatitis C virus in U.S. blood donors. J Clin Microbiol 29:551–556, 1991PubMedGoogle Scholar
  14. 14.
    Esteban JI, Gonzalez A, Hernandez JE, Vilandomiu L, Sanchez C, Lopes-Talavera C, Lucea D, Martin-Vega C, Vidal X, Esteban R, Guardia J: Evaluation of antibody to hepatitis C virus in a study of transfusion associated hepatitis. N Engl J Med 323:1107–1112, 1990PubMedGoogle Scholar
  15. 15.
    Kuhnl P, Seidl S, Stangel W, Beyer J, Sibrowski W, Elik J: Antibody to hepatitis C virus in German blood donors. Lancet 2:324, 1989Google Scholar
  16. 16.
    Watanabe J, Minegishi K, Mitsumori T, Ishifuji M, Oguchi T, Ueda M, Tokunaga E, Tanaka E, Kiyosawa K, Furuta S: Prevalence of anti-HCV antibody in blood donors in the Tokyo area. Vox Sang 59:86–88, 1990PubMedGoogle Scholar
  17. 17.
    Schattner A: Interferons and autoimmunity. Am J Med Sci 295:523–544, 1988Google Scholar
  18. 18.
    Farrar WL, Birchenall-Sparks MC, Young HB: Interleukin 2 induction of interferon-gamma in RNA synthesis. J Immunol 127:3836–3840, 1986Google Scholar
  19. 19.
    Ballardini G, Bianchi FB, Doniach D, Mirakian R, Pisi E, Bottazzo GF: Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: Relevance to pathogenesis. Lancet 2:1009–1113, 1984PubMedGoogle Scholar
  20. 20.
    Karlsson-Parra A, Burman P, Hagberg H, Oberg K, Alm G, Klareskog L, Karlsson FA: Autoantibodies to epithelial cells in patients on long-term therapy with leukocyte-derived interfer-on-alpha (IFN-α). Clin Exp Immunol 81:72–75, 1990PubMedGoogle Scholar
  21. 21.
    Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watoson AJ, James OFW: Positive antimitochondrial antibody but normal alkaline phosphatase: Is this primary biliary cirrhosis? Hepatology 6:1279–1284, 1986PubMedGoogle Scholar
  22. 22.
    Groote JD, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, Schmid M, Thaler H, Uehlinger E, Wepler W: A classification of chronic hepatitis. Lancet 2:626–628, 1968PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • T. Maeda
    • 2
    • 1
  • S. Onishi
    • 2
    • 1
  • T. Miura
    • 2
    • 1
  • S. Iwamura
    • 2
    • 1
  • A. Tomita
    • 2
    • 1
  • T. Saibara
    • 2
    • 1
  • Y. Yamamoto
    • 2
    • 1
  1. 1.Miura ClinicKochiJapan
  2. 2.First Department of Internal MedicineKochi Medical SchoolKochiJapan

Personalised recommendations